Antiviral treatment of patients with oseltamivir-resistant and oseltamivir-susceptible seasonal influenza A (H1N1) infection during the 2007-2008 influenza season in the United States

Clinical Infectious Diseases

Volumn 50, Issue 4, 2010, Pages 621-622

  Dharan, Nila J ^a,b   Gubareva, Larisa V ^a   Klimov, Alexander I ^a   Fiare, Anthony E ^a   Bresee, Joseph S ^a   Fry, Alicia M ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; OSELTAMIVIR; RIMANTADINE;

ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; CONVALESCENCE; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED STATES;

ANTIVIRAL AGENTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; OSELTAMIVIR; TREATMENT OUTCOME; UNITED STATES;

EID: 75749092970     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/650178     Document Type: Letter

References (3)

1. Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A (H1N1) virus in the United States. JAMA 2009;301(10):1034-1041.
2. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52(9):3284-3292.
3. Kawai N, Ikematsu H, Iwaki N, et al. Clinical effectiveness of oseltamivir for influenza A (H1N1) virus with H274Y neuraminidase mutation. J Infect 2009;59(3):207-212.